Unicycive Therapeutics Inc (UNCY NASDAQ) stock market data APIs
$6.2646
0.32(5.1%)
as of December 5, 2025
Try our APIs with
free plan!
Unicycive Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also evaluates licensing of technologies and drugs for orphan diseases, other renal, liver, and other metabolic diseases affecting fibrosis and inflammation. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd to develop and commercialize oxylanthanum carbonate; Sphaera Pharma Pte. Ltd.; Syneos Health LLC to develop of UNI-494; Inotiv for preclinical trial and related services for oxylanthanum carbonate and UNI-494; Lee's Pharmaceutical (HK) Limited; and Lotus International Pte Ltd for the development, registration filing, and approval for oxylanthanum carbonate. The company was incorporated in 2016 and is based in Los Altos, California.
Prev. Close
6.2646
Open
6.5861
High
6.6009
Low
6.1556
52 wk Range
3.71-11
Market Cap
134 M
Shares Outstanding
21 491 K
EPS
-0.33
Beta
1.833
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Unicycive Therapeutics Inc data using free add-ons & libraries
Get Unicycive Therapeutics Inc Fundamental Data
Unicycive Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -31 523 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-12
- EPS/Forecast: -0.0662
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Unicycive Therapeutics Inc News
New
Important Notice to Long-Term Shareholders of Five Below, Inc. (NASDAQ: FIVE); Molina Healthcare, Inc. (NYSE: MOH); Synopsys, Inc. (NASDAQ: SNPS); and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office Investigates Claims on Your Behalf
PHILADELPHIA, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Five Below, Inc. (NASDAQ: FIVE) – Class Action Survives Motion to Dismiss: Grabar Law Office is investigating claims on behalf of shareholders of ...
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office is Investigating Claims on Your Behalf
PHILADELPHIA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (NASDAQ: CYTK): Grabar Law Office is investigating claims on behalf of shareholders of Cytokinetics, Inc. (NASDAQ: CYTK). The inv...
After-Hours Spotlight: Jasper, NRx, Unicycive, Spruce, Evaxion, Solana, Protara Gain Post-Close
(RTTNews) - Several biotechnology and pharmaceutical companies posted notable gains in after-hours trading on Monday, following a mix of corporate updates and upcoming event announcements. Jasper The...
Unicycive Therapeutics to Participate in Upcoming Investor Events in December
LOS ALTOS, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the �...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
